Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan.
Institute for Research Promotion, Oita University, Oita, Japan.
Sci Rep. 2017 Jul 28;7(1):6819. doi: 10.1038/s41598-017-07208-6.
Various methods can correct presbyopia, but all require devices or surgeries. Recently, supplements or warming devices to relieve presbyopic symptoms have been developed, but no eye drops have been developed. We screened certain compounds possibly related to lens degeneration and identified pirenoxine, which has been used for cataracts, as a possible new pharmacologic treatment for presbyopia. We first researched the anti-presbyopic activity of pirenoxine in rats. The lens elasticity significantly (p = 0.028) increased with exposure to tobacco smoke for 12 days, and pirenoxine eye drops significantly (p < 0.001) suppressed lens hardening, which causes presbyopia in humans. In a parallel randomized controlled clinical study of the subjects in their fifth decade of life, the objective accommodative amplitude (AA) decreased significantly (p < 0.01) by 0.16 diopter (D) in the control group, and there was no detectable change in the treatment group after a 6-month treatment period, suggesting that pirenoxine eye drops might prevent progression of presbyopia. Subjects in their sixth decade of life, in whom the AA was already nearly 0 D, did not show similar results. Pirenoxine eye drops might be a new and the first pharmacologic treatment for preventing progression of presbyopia.
各种方法都可以矫正远视，但都需要使用设备或手术。最近，缓解远视症状的补充剂或加热设备已经开发出来，但还没有开发出眼药水。我们筛选了某些可能与晶状体变性相关的化合物，并确定了吡诺克辛，它已被用于白内障，作为治疗远视的一种新的潜在药物治疗方法。我们首先研究了吡诺克辛在大鼠中的抗远视活性。晶状体弹性显著增加（p=0.028），与暴露于香烟烟雾 12 天有关，吡诺克辛滴眼液显著抑制晶状体硬化，这是导致人类远视的原因。在一项针对 50 岁出头的受试者的平行随机对照临床试验中，对照组的客观调节幅度（AA）显著下降（p<0.01）0.16 屈光度（D），治疗组在 6 个月的治疗期间没有检测到变化，这表明吡诺克辛滴眼液可能可以预防远视进展。AA 已经接近 0 D 的 60 岁出头的受试者没有出现类似的结果。吡诺克辛滴眼液可能是预防远视进展的一种新的、也是第一种药物治疗方法。
